<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02339376</url>
  </required_header>
  <id_info>
    <org_study_id>2014P000216</org_study_id>
    <nct_id>NCT02339376</nct_id>
  </id_info>
  <brief_title>Treating Deep Seizure Foci With Noninvasive Surface Brain Stimulation</brief_title>
  <official_title>Treating Deep Seizure Foci With Noninvasive Surface Brain Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <brief_summary>
    <textblock>
      The overall goal of this study is to open up the promising treatment of repetitive&#xD;
      transcranial magnetic stimulation (rTMS), which has been shown to be effective against&#xD;
      seizures in patients with surface neocortical foci, to a much larger population of patients&#xD;
      with mesial temporal lobe epilepsy (MTLE) and other forms of epilepsy with deep foci, who are&#xD;
      not currently considered good rTMS candidates.&#xD;
&#xD;
      The investigators hypothesize that rTMS can modulate the hyperexcitable state in patients&#xD;
      with deep seizure foci by targeting its usage to accessible cortical partner regions. In this&#xD;
      study the investigators aim 1) to map the functional connectivity of the epileptogenic mesial&#xD;
      temporal lobe in patients with medically refractory mesial temporal lobe epilepsy; and 2) to&#xD;
      perform a randomized controlled assessment of repetitive transcranial magnetic stimulation&#xD;
      protocols applied to specific neocortical targets in mesial temporal lobe epilepsy. The&#xD;
      methods used in this study will include magnetic resonance imaging (MRI) of the brain,&#xD;
      electroencephalography (EEG), and transcranial magnetic stimulation (TMS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">March 10, 2021</completion_date>
  <primary_completion_date type="Actual">March 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seizure frequency</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interictal epileptiform discharge frequency on electroencephalogram</measure>
    <time_frame>at 12 week follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Epilepsy, Temporal Lobe</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-frequency repetitive transcranial magnetic stimulation: 30-minute sessions of 1-Hz continuous stimulation at 95% resting motor threshold, with one session each day over 10 consecutive weekdays</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-frequency repetitive transcranial magnetic stimulation: 30-minute sessions of 10-Hz continuous stimulation at 110% resting motor threshold, with one session each day over 10 consecutive weekdays</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham repetitive transcranial magnetic stimulation: use of a specially fabricated coil that provides no magnetic stimulation but has a similar appearance and creates an auditory artifact that mimics TMS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low-frequency repetitive transcranial magnetic stimulation</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Nexstim eXimia TMS stimulator with neuronavigation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High-frequency repetitive transcranial magnetic stimulation</intervention_name>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Nexstim eXimia TMS stimulator with neuronavigation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham repetitive transcranial magnetic stimulation</intervention_name>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of mesial temporal lobe epilepsy based on the combination of clinical&#xD;
             semiology, neuroimaging findings, and electroencephalogram results.&#xD;
&#xD;
          -  At least 1 seizure with loss of awareness per 4-week period, on average, despite the&#xD;
             use of antiepileptic drugs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior brain surgery or exposure to transcranial magnetic stimulation&#xD;
&#xD;
          -  Rapidly progressive brain lesions&#xD;
&#xD;
          -  Inability to tolerate MRI or TMS&#xD;
&#xD;
          -  Specific MRI or TMS contraindication as set forth in standard protocols of our&#xD;
             institution&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard S Chang, MD, MMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 8, 2015</study_first_submitted>
  <study_first_submitted_qc>January 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2015</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Bernard Chang</investigator_full_name>
    <investigator_title>Associate Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Epilepsy, Temporal Lobe</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

